Recurrent Multiple Myeloma Following Renal Transplantation: A Case Report

Taheri, Diana; Chehrei, Ali; Fesharakizadeh, Mehdi; Seyrafean, S.; Shahidi, Shahrzad; Emami, Alireza; Taheri, Shahram; Azani, Mehdi

doi:10.1016/j.transproceed.2007.02.015

Cited by 7 publications

(9 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with multiple myeloma can receive kidney transplants (13;46), and the malignancy can recur following transplantation (20;47;48). However, several points argue against this interpretation in our study.…”

Section: Discussionmentioning

confidence: 99%

“…Additionally, risk factors for PCN among transplant recipients, including the time of onset after transplantation, underlying medical conditions, and the role of immunosuppressive medications, have not been fully evaluated. Detection of EBV in PCNs has been described in case reports or small series (15)(16)(17)(18)(19)(20)(21)(22)(23), but the frequency of EBV infection is unknown, and there are no data relating PCN risk to EBV serostatus at the time of transplantation.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Plasma Cell Neoplasms in US Solid Organ Transplant Recipients

Engels

Clarke

Pfeiffer

et al. 2013

American Journal of Transplantation

View full text Add to dashboard Cite

Transplant recipients have elevated risk for plasma cell neoplasms (PCNs, comprising multiple myeloma and plasmacytoma), but little is known about risk factors in the transplant setting. Through linkage of the U.S. solid organ transplant registry with 15 state/regional cancer registries, we identified 140 PCNs in 202,600 recipients (1987–2009). PCN risk was 1.8-fold increased relative to the general population (standardized incidence ratio [SIR] 1.80, 95%CI 1.51–2.12). Among cases, 102 were multiple myeloma (SIR 1.41) and 38 were plasmacytoma (SIR 7.06). PCN incidence increased with age, but due to the rarity of PCNs in younger people in the general population, SIRs were highest in younger transplant recipients (p=0.03). PCN risk was especially high in recipients who were Epstein-Barr virus (EBV) seronegative at transplantation (SIR 3.93). EBV status was known for 18 tumors, of which 7 (39%) were EBV positive. Following liver transplantation, PCN risk was higher in recipients with cholestatic liver disease (SIR 2.78); 5 of these cases had primary biliary cirrhosis (PBC). A role for primary EBV infection after transplantation is supported by the increased PCN risk in young EBV seronegative recipients and the presence of EBV in tumors. PBC may be another risk factor, perhaps by causing chronic immune activation.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Plasma Cell Neoplasms in US Solid Organ Transplant Recipients

Engels

Clarke

Pfeiffer

et al. 2013

American Journal of Transplantation

View full text Add to dashboard Cite

show abstract

“…Experts have reached opposing conclusions as most available data have been anecdotal and pertain to retrospective analyses. [27][28][29][30][31] The main argument against the use of kidney allografting in MIDD is based on the risk of recurrence in the allograft as well as the overall poor prognosis because of the underlying hematologic malignancy. However, there is little information in these reports regarding the hematologic response of patients prior to kidney transplantation.…”

Section: Discussionmentioning

confidence: 99%

High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease

Hassoun

Flombaum

D’Agati

et al. 2008

Bone Marrow Transplant

View full text Add to dashboard Cite

“…Taheri et al. (16) have reported a case of recurrent myeloma of the allograft kidney with calcified tubular crystals and casts 18 months after transplant. Although kappa LCs are more commonly reported, Tanenbaum et al.…”

Section: Discussionmentioning

confidence: 99%

“…Myeloma in transplant kidney can recur despite achieving successful remission prior to transplantation. Taheri et al (16) have reported a case of recurrent myeloma of the allograft kidney with calcified tubular crystals and casts 18 months after transplant. Although kappa LCs are more commonly reported, Tanenbaum et al (17) have reported a case of lambda LC deposition with glomerular involvement in a renal allograft recipient.…”

Section: Discussionmentioning

confidence: 99%

Myeloma kidney with isolated tubulointerstitial light chain deposition in a renal allograft

Balamuthusamy¹,

Hamrahian²,

Zhang³

et al. 2009

Clinical Transplantation

View full text Add to dashboard Cite

Myeloma kidney and myeloma-associated renal disorders including light chain deposition disease can occur as recurrent or de novo disease in renal allografts. These kidney disorders usually manifest with worsening allograft function and proteinuria. Identification of the precise cause of kidney disorder often requires kidney biopsy and demonstration of monoclonal light chains in the kidney. Here, we present an unusual case of light chain nephropathy in a living-related kidney transplant recipient involving light chain crystallization in the proximal tubule occurring within less than three months after transplant. The etiology of renal failure prior to transplant in our patient is not clear. To the best of our knowledge, the ultrastructural changes seen in our patient have not been described in literature previously. Our patient was treated with steroids, which resulted in short-term improvement in allograft dysfunction.

show abstract

Recurrent Multiple Myeloma Following Renal Transplantation: A Case Report

Cited by 7 publications

References 10 publications

Plasma Cell Neoplasms in US Solid Organ Transplant Recipients

Plasma Cell Neoplasms in US Solid Organ Transplant Recipients

High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease

Myeloma kidney with isolated tubulointerstitial light chain deposition in a renal allograft

Contact Info

Product

Resources

About